Targeting the EGF receptor for ovarian cancer therapy - PubMed (original) (raw)

Targeting the EGF receptor for ovarian cancer therapy

Reema Zeineldin et al. J Oncol. 2010.

Abstract

Ovarian carcinoma is the leading cause of death from gynecologic malignancy in the US. Factors such as the molecular heterogeneity of ovarian tumors and frequent diagnosis at advanced stages hamper effective disease treatment. There is growing emphasis on the identification and development of targeted therapies to disrupt molecular pathways in cancer. The epidermal growth factor (EGF) receptor is one such protein target with potential utility in the management of ovarian cancer. This paper will discuss contributions of EGF receptor activation to ovarian cancer pathogenesis and the status of EGF receptor inhibitors and EGF receptor targeted therapies in ovarian cancer treatment.

PubMed Disclaimer

Similar articles

• Heparin-binding EGF-like growth factor is a promising target for ovarian cancer therapy.
  Miyamoto S, Hirata M, Yamazaki A, Kageyama T, Hasuwa H, Mizushima H, Tanaka Y, Yagi H, Sonoda K, Kai M, Kanoh H, Nakano H, Mekada E. Miyamoto S, et al. Cancer Res. 2004 Aug 15;64(16):5720-7. doi: 10.1158/0008-5472.CAN-04-0811. Cancer Res. 2004. PMID: 15313912
• Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy.
  Tsujioka H, Yotsumoto F, Hikita S, Ueda T, Kuroki M, Miyamoto S. Tsujioka H, et al. Curr Opin Obstet Gynecol. 2011 Feb;23(1):24-30. doi: 10.1097/GCO.0b013e3283409c91. Curr Opin Obstet Gynecol. 2011. PMID: 20966750 Review.
• Crosstalk between EGFR and TrkB enhances ovarian cancer cell migration and proliferation.
  Qiu L, Zhou C, Sun Y, Di W, Scheffler E, Healey S, Kouttab N, Chu W, Wan Y. Qiu L, et al. Int J Oncol. 2006 Oct;29(4):1003-11. Int J Oncol. 2006. PMID: 16964397
• Discovery of HB-EGF binding peptides and their functional characterization in ovarian cancer cell lines.
  Shen Y, Ruan L, Lian C, Li R, Tu Z, Liu H. Shen Y, et al. Cell Death Discov. 2019 Mar 25;5:82. doi: 10.1038/s41420-019-0163-9. eCollection 2019. Cell Death Discov. 2019. PMID: 30937184 Free PMC article.
• The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer.
  Palayekar MJ, Herzog TJ. Palayekar MJ, et al. Int J Gynecol Cancer. 2008 Sep-Oct;18(5):879-90. doi: 10.1111/j.1525-1438.2007.01144.x. Epub 2007 Dec 5. Int J Gynecol Cancer. 2008. PMID: 18053062 Review.

Cited by

• Transforming growth factor alpha (TGFα) regulates granulosa cell tumor (GCT) cell proliferation and migration through activation of multiple pathways.
  Wang C, Lv X, Jiang C, Cordes CM, Fu L, Lele SM, Davis JS. Wang C, et al. PLoS One. 2012;7(11):e48299. doi: 10.1371/journal.pone.0048299. Epub 2012 Nov 14. PLoS One. 2012. PMID: 23155381 Free PMC article.
• Flow induces epithelial-mesenchymal transition, cellular heterogeneity and biomarker modulation in 3D ovarian cancer nodules.
  Rizvi I, Gurkan UA, Tasoglu S, Alagic N, Celli JP, Mensah LB, Mai Z, Demirci U, Hasan T. Rizvi I, et al. Proc Natl Acad Sci U S A. 2013 May 28;110(22):E1974-83. doi: 10.1073/pnas.1216989110. Epub 2013 May 3. Proc Natl Acad Sci U S A. 2013. PMID: 23645635 Free PMC article.
• Palliative systemic therapy for women with recurrent epithelial ovarian cancer: current options.
  Elit L, Hirte H. Elit L, et al. Onco Targets Ther. 2013;6:107-18. doi: 10.2147/OTT.S30238. Epub 2013 Feb 26. Onco Targets Ther. 2013. PMID: 23459506 Free PMC article.
• EGFR/HER-targeted therapeutics in ovarian cancer.
  Wilken JA, Badri T, Cross S, Raji R, Santin AD, Schwartz P, Branscum AJ, Baron AT, Sakhitab AI, Maihle NJ. Wilken JA, et al. Future Med Chem. 2012 Mar;4(4):447-69. doi: 10.4155/fmc.12.11. Future Med Chem. 2012. PMID: 22416774 Free PMC article. Review.
• The cell surface glycoprotein CUB domain-containing protein 1 (CDCP1) contributes to epidermal growth factor receptor-mediated cell migration.
  Dong Y, He Y, de Boer L, Stack MS, Lumley JW, Clements JA, Hooper JD. Dong Y, et al. J Biol Chem. 2012 Mar 23;287(13):9792-9803. doi: 10.1074/jbc.M111.335448. Epub 2012 Feb 7. J Biol Chem. 2012. PMID: 22315226 Free PMC article.

References

1. 1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA: Cancer Journal for Clinicians. 2008;58(2):71–96. - PubMed
2. 1. Bast RC, Jr., Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nature Reviews Cancer. 2009;9(6):415–428. - PMC - PubMed
3. 1. Scully R, Young R, Clement P. Tumors of the ovary, maldeveloped gonads, fallopian tube, and broad ligament. In: Rosia J, Sobin L, editors. Atlas of Tumor Pathology. Fascicle 23. Washington, DC, USA: Armed Forces Institute of Pathlogy; 1998.
4. 1. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nature Reviews Cancer. 2009;9(3):167–181. - PubMed
5. 1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57–70. - PubMed

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Hindawi Limited
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database